Occult synchronous liver metastasis from perihilar cholangiocarcinoma.
Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms
/ diagnostic imaging
Biomarkers, Tumor
Biopsy
Diagnosis, Differential
Female
Humans
Incidence
Klatskin Tumor
/ diagnostic imaging
Liver Neoplasms
/ diagnosis
Male
Middle Aged
Neoplasm Staging
Neoplasms, Multiple Primary
/ diagnosis
Preoperative Care
Retrospective Studies
Survival Analysis
Treatment Outcome
Journal
Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
26
02
2019
revised:
15
04
2019
accepted:
29
04
2019
pubmed:
27
6
2019
medline:
21
1
2020
entrez:
26
6
2019
Statut:
ppublish
Résumé
No authors have reported occult liver metastases from perihilar cholangiocarcinoma (PHCC), which are defined as intrahepatic metastases that are overlooked by preoperative workup and intraoperative inspection but are detected by final pathology. The aim of this study was to clarify the features of such unappreciated metastases. We reviewed retrospectively the medical records of patients with PHCC treated between 2001 and 2016 with attention to liver metastases. During the study interval, 945 consecutive patients with PHCC were treated, including 260 unresected and 685 resected patients (672 with hepatectomy and 13 without). Of these, 36 patients had overt liver metastases. Of the 672 hepatectomized patients, 21 (3.1%) patients had occult liver metastases with a median number of 1 (range 1-6). When compared between occult and overt metastases, the diameter was smaller in the former (5 mm vs 12 mm, P < .001). When compared between the 21 patients with occult metastases and the 645 hepatectomized patients without liver metastases, microscopic venous invasion and lymph node metastases were observed frequently in the patients with occult metastases. Survival for these 21 patients with occult metastases was better than that for the 36 patients with overt metastases (median survival time; 17.1 vs 7.4 months, P < .01). Occult liver metastases from PHCC are not extremely rare. Meticulous handling of the resected specimens is crucial to detect such metastases. Although patients with occult metastases had advanced stages of the disease, their survival was better than that for patients with overt metastases.
Sections du résumé
BACKGROUND
No authors have reported occult liver metastases from perihilar cholangiocarcinoma (PHCC), which are defined as intrahepatic metastases that are overlooked by preoperative workup and intraoperative inspection but are detected by final pathology. The aim of this study was to clarify the features of such unappreciated metastases.
METHODS
We reviewed retrospectively the medical records of patients with PHCC treated between 2001 and 2016 with attention to liver metastases.
RESULTS
During the study interval, 945 consecutive patients with PHCC were treated, including 260 unresected and 685 resected patients (672 with hepatectomy and 13 without). Of these, 36 patients had overt liver metastases. Of the 672 hepatectomized patients, 21 (3.1%) patients had occult liver metastases with a median number of 1 (range 1-6). When compared between occult and overt metastases, the diameter was smaller in the former (5 mm vs 12 mm, P < .001). When compared between the 21 patients with occult metastases and the 645 hepatectomized patients without liver metastases, microscopic venous invasion and lymph node metastases were observed frequently in the patients with occult metastases. Survival for these 21 patients with occult metastases was better than that for the 36 patients with overt metastases (median survival time; 17.1 vs 7.4 months, P < .01).
CONCLUSION
Occult liver metastases from PHCC are not extremely rare. Meticulous handling of the resected specimens is crucial to detect such metastases. Although patients with occult metastases had advanced stages of the disease, their survival was better than that for patients with overt metastases.
Identifiants
pubmed: 31235246
pii: S0039-6060(19)30240-5
doi: 10.1016/j.surg.2019.04.029
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-296Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.